Clinical trials: Multiple-drug Resistance
E. Coli Infection, Multi-antibiotic Resistance
Perinatal Transmission of MDR Bacteria
The investigators aim to conduct a prospective surveillance study of mothers and their infants born vaginally or by scheduled C-section and who are admitted to Northwestern Medicine Prentice Women's Hospital to determine the…
- Trial name
- ACQUIRE (NCT06148480)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Tuberculosis Multi Drug Resistant Active, Rifampin-Resistant Pulmonary Tuberculosis
Oral Nutritional Supplementation and Weight Changes During Therapy in Malnourished Patients With Resistant Tuberculosis: A Clinical Trial
Tuberculosis increases energy demands and protein breakdown, leading to muscle wasting. Malnutrition and minimal weight gain less than 5% in first two months predict treatment failure.
- Conditions
- Tuberculosis Multi Drug Resistant Active, Rifampin-Resistant Pulmonary Tuberculosis, Pre-xdr tb
- Trial name
- NCT07058233
- Testing
- Oral nutritional supplementation
- Where
- Indonesia
- Volunteers
- 70 people
- Sponsor
- RSUP Persahabatan
HIV-1-infection
Investigating the Optimal Management of Dolutegravir Resistance
The goal of this study is to address the gap in published data on viral suppression among people meeting the criteria for virologic failure on dolutegravir (DTG)-based ART regimens without a change in regimen.
- Trial name
- NCT06762054
- Testing
- Continue DTG-based antiretroviral therapy, Enhanced adherence counselling
- Where
- 9 sites in Kenya, Lesotho and 2 more
- Volunteers
- 6,600 people
- Sponsor
- University of Nairobi
Multiple Myeloma
Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma
Multiple Myeloma (MM) is the more common hematological neoplastic disease second only to Hodgkin lymphoma. In MM patients, mutated genes are mainly KRAS (23%), NRAS (20%), FAM46C (11%), DIS3 (11%) e TP53 (8%).
- Trial name
- TEDROMM (NCT05888636)
- Testing
- ChIP-seq, NGS, ATAC-seq
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Regina Elena Cancer Institute
Linezolid, Tuberculosis Multi Drug Resistant Active
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023.
- Conditions
- Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)
- Trial name
- PLOT-TB (NCT07477119)
- Testing
- Linezolid dose personalization based on TDM
- Where
- Guinea
- Volunteers
- 150 people
- Sponsor
- Marco Schiuma
Pulmonary Tuberculosis
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of bedaquiline plus PA-824 plus linezolid after 6 months of treatment (option for 9 months for participants who remain culture…
- Trial name
- NCT02333799
- Testing
- Bedaquiline, PA-824, Linezolid
- Where
- 3 sites in South Africa
- Volunteers
- 109 people
- Sponsor
- Global Alliance for TB Drug Development
Bone and Osteoarticular Infection Due to MDR M. Tuberculosis Strains
Bone Resistant Tuberculosis
The recommendations for the treatment of MDR tuberculosis are based on pulmonary tuberculosis since there is a lack of specific recommendations for TB bone and osteoarticular disease, including those due to multi drug resistance…
- Trial name
- TboneR (NCT04928378)
- Testing
- Descriptive retrospective study
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infections, Bacterial
In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance
Observational: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals.
- Trial name
- NCT01132417
- Testing
- In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
- Where
- Saudi Arabia
- Volunteers
- 500 people
- Sponsor
- King Faisal University
Cirrhosis, Bacterial Infections
International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections
What is this study about? This study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high…
- Conditions
- Cirrhosis, Bacterial Infections, Multidrug Resistance
- Trial name
- NCT06634940
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- Hospital Italiano de Buenos Aires
HIV Infections
A Comparison of Two Anti-HIV Treatment Plans
The purpose of this study is to compare 2 treatment plans to try to increase the effects of anti-HIV drugs in patients who are resistant to the drug effects.
- Trial name
- NCT00005915
- Where
- 21 sites in United States
- Volunteers
- 480 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Synergy Between Plasmid Inhibitors and Combined Antibiotics
Synergistic Effect of Plasmid Inhibitors and Antimicrobial Drugs Against Clinical MDR-hvKP
1. Screening for MDR-hvKP causing VAP in patients admitted to chest ICU in Assiut University Hospital. 2. In vitro evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin against…
- Trial name
- NCT05932355
- Volunteers
- 50 people
- Sponsor
- Assiut University
Patients With Multi Drug Resistant Gram-negative Bacteria, Colistin Resistance in Bacteria
Phenotypic and Genotypic Detection of Colistin Resistance
Evaluation of the disk elution test as reliable routine method for detection of colistin resistant among multidrug resistant gram-negative bacteria compared with broth microdilution.
- Trial name
- NCT07487116
- Testing
- disk elution test
- Volunteers
- 90 people
- Sponsor
- Assiut University
Breast Cancer, Cancer
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel.
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma
- Trial name
- NCT00001383
- Testing
- PSC 833, paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Infections Resistant to Multiple Drugs, Bacterial Infections
Multi-Drug Resistant Organism Network
This study is specifically designed to provide observational data which can be used to help in the design of future randomized clinical trials on both therapeutics and diagnostics for MDRO infections.
- Trial name
- MDRO Network (NCT03646227)
- Testing
- Standard of Care
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 6,496 people
- Sponsor
- Duke University
Kidney Neoplasms, Neoplasm Metastasis
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days.
- Trial name
- NCT00001570
- Testing
- PSC 833, vinblastine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections, Tuberculosis
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB).
- Trial name
- NCT00000796
- Testing
- Cycloserine, Ethionamide, Capreomycin sulfate
- Where
- 21 sites in United States
- Volunteers
- 525 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adults Patients, With Fecal Carriage of Multi-Drug Resistant Enterobacterales (MDR-E)
Household Transmission Dynamics of Multidrug Resistant Enterobacterales
The HOME study will prospectively follow a cohort of Multi-Drug Resistant Enterobacterales (MDR-E) carriers after hospital discharge, and their related household members over a 3-month period.
- Trial name
- HOME (NCT05798364)
- Where
- France
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Seizures
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
This is a Phase 1/2, open-label trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral Solution in a sequential fashion.
- Trial name
- NCT02324673
- Testing
- Cannabidiol Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- INSYS Therapeutics Inc
Autoimmune Diseases, Systemic Lupus Erthematosus
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
this is an investigator-initiated trial aimed at evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy
- Trial name
- NCT06792799
- Testing
- anti-CD19/BCMA CAR NK cells (KN5601)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Multi-drug Resistant Tuberculosis
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
PandrTB is a study of the pharmacokinetics(PK) and pharmacodynamics(PD) of bedaquiline, delamanid, clofazimine, linezolid, moxifloxacin, levofloxacin and pyrazinamide used in novel combinations to treat multidrug-resistant…
- Trial name
- PandrTB (NCT03827811)
- Where
- 7 sites in Kazakhstan, Lesotho and 4 more
- Volunteers
- 625 people
- Sponsor
- University of Cape Town